Sanofi (NASDAQ:SNY) Receives $57.50 Consensus PT from Analysts

by · The Cerbat Gem

Sanofi (NASDAQ:SNY – Get Free Report) has received an average rating of “Moderate Buy” from the four ratings firms that are currently covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $57.50.

Several brokerages recently commented on SNY. StockNews.com lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 7th. Citigroup raised shares of Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th.

Read Our Latest Stock Report on SNY

Sanofi Stock Performance

Sanofi stock opened at $47.96 on Thursday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $58.97. The stock has a fifty day moving average of $52.80 and a two-hundred day moving average of $52.15. The company has a market capitalization of $121.71 billion, a price-to-earnings ratio of 24.74, a PEG ratio of 1.23 and a beta of 0.61.

Sanofi (NASDAQ:SNY – Get Free Report) last released its earnings results on Friday, October 25th. The company reported $1.57 EPS for the quarter, topping the consensus estimate of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The firm had revenue of $13.44 billion during the quarter, compared to analysts’ expectations of $16.59 billion. During the same period in the previous year, the company earned $2.55 EPS. Sanofi’s revenue for the quarter was up 12.3% on a year-over-year basis. On average, analysts anticipate that Sanofi will post 4.28 EPS for the current fiscal year.

Institutional Investors Weigh In On Sanofi

Several large investors have recently made changes to their positions in SNY. B. Riley Wealth Advisors Inc. increased its holdings in Sanofi by 32.4% in the 1st quarter. B. Riley Wealth Advisors Inc. now owns 20,925 shares of the company’s stock valued at $1,122,000 after purchasing an additional 5,117 shares in the last quarter. Tidal Investments LLC purchased a new stake in shares of Sanofi in the first quarter worth about $228,000. Atria Investments Inc boosted its position in shares of Sanofi by 31.1% in the first quarter. Atria Investments Inc now owns 98,878 shares of the company’s stock worth $4,805,000 after buying an additional 23,463 shares during the period. Redwood Grove Capital LLC raised its holdings in shares of Sanofi by 9.1% during the 1st quarter. Redwood Grove Capital LLC now owns 261,154 shares of the company’s stock valued at $12,692,000 after buying an additional 21,710 shares during the period. Finally, Cetera Investment Advisers lifted its position in Sanofi by 245.4% during the 1st quarter. Cetera Investment Advisers now owns 178,349 shares of the company’s stock worth $8,668,000 after acquiring an additional 126,712 shares in the last quarter. Institutional investors and hedge funds own 10.04% of the company’s stock.

About Sanofi

(Get Free Report

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

Featured Articles